Roshan Yoganathan
Dr. Yoganathan completed his undergraduate degree at the University of Toronto (2004) with a specialization in the Engineering Science program (Biomedical option), considered to be the top engineering program in Canada. Desiring to expand his view on biomedical research, he travelled overseas to the University of New South Wales (UNSW) (Sydney, Australia) where he did his Masters (2006) and PhD (2010) in Biomedical Engineering. His Master’s thesis focused on producing a biomaterial nanocomposite with robust biomechanical properties. His PhD dissertation focused on the use of green technology and high pressure systems to synthesize biopolymers for tissue engineering and drug delivery applications. The dissertation also involved a collaborative project on soft biomaterials intended for laryngeal cancer with Dr. Robert Langer’s Lab at the Massachusetts Institute of Technology (MIT) (Boston, USA). As of 2011, the work with Dr. Langer has progressed towards commercialization and is about to commence clinical trials.
Dr. Yoganathan is interested in the implementation of material and pharmaceutical science to develop anti-cancer drug delivery systems and tissue engineering devices. Dr. Yoganathan was the recipient of the inaugural 2010 MITACS Elevate Industrial Research Fellowship Award. With Professor Christine Allen (Faculty of Pharmacy, University of Toronto) and Dr. Joseph Elliot (President and CEO, Receptor Therapeutics), he worked on the pre-clinical development and optimization of a polymer-lipid drug delivery formulation for the peri-operative treatment of ovarian cancer. Dr. Yoganathan has given presentations on biomaterials and drug delivery at MIT, UNSW and most recently at the Beijing University of Chemical Technology (BUCT, Beijing, China). At BUCT, he has also helped establish a new pharmaceutical research laboratory.
His future aspirations include utilizing his multi-disciplinary background in biomedical engineering, pharmaceutical science, microbiology, analytical chemistry, business development and communication to translate cutting-edge research to marketable technology.
Dr. Yoganathan is interested in the implementation of material and pharmaceutical science to develop anti-cancer drug delivery systems and tissue engineering devices. Dr. Yoganathan was the recipient of the inaugural 2010 MITACS Elevate Industrial Research Fellowship Award. With Professor Christine Allen (Faculty of Pharmacy, University of Toronto) and Dr. Joseph Elliot (President and CEO, Receptor Therapeutics), he worked on the pre-clinical development and optimization of a polymer-lipid drug delivery formulation for the peri-operative treatment of ovarian cancer. Dr. Yoganathan has given presentations on biomaterials and drug delivery at MIT, UNSW and most recently at the Beijing University of Chemical Technology (BUCT, Beijing, China). At BUCT, he has also helped establish a new pharmaceutical research laboratory.
His future aspirations include utilizing his multi-disciplinary background in biomedical engineering, pharmaceutical science, microbiology, analytical chemistry, business development and communication to translate cutting-edge research to marketable technology.
less
InterestsView All (10)
Uploads
Papers by Roshan Yoganathan
Areas covered: This review provides an overview of recent advances in DDS strategies for the treatment ovarian cancers. Nano-sized systems, including nanoparticles, micelles, liposomes and drug conjugates; microspheres; implants and injectable depots are discussed. The advantages, limitations and clinical potential of these strategies are also outlined.
Expert opinion: Nano-sized DDS enable passive targeting to tumors due to their size, and further improvements in tumor localization can be made using targeting moieties. Microspheres, implants and injectable depots have been investigated for peritoneal localized and sustained therapy. Overall, the benefits of using DDS for ovarian cancer therapy include higher drug levels at the diseased site, circumvention of drug resistance mechanisms, minimization of non-specific toxicities, improvements in solubility of poorly soluble drugs and elimination of toxicities associated with conventionally used pharmaceutical excipients.
product that may be used as a contrasting agent for MRI. There are several methods that can be employed to coat SPIONs.
However, many of the current methods employ toxic organic solvents which can be difficult to remove from the product
solution. The encapsulation and characterization of SPIONs in Eudragit was done using a supercritical antisolvent system
(SAS) with ethanol as the solvent and supercritical carbon dioxide (SC-CO2) as the antisolvent. Particles of diameters less
than 200 nm were produced which had preserved superparamagnetic properties. An encapsulation efficiency of 70% was
achieved.
There are distinct turning points when biomaterial research is thought to have evolved. I believe we are currently in the third generation and slowly shifting to the fourth (more on this later).
compounds (VOCs) is a practice that is being limited and minimized world-wide. These VOCs are not only damaging to the environment, but are also an occupational hazard. The polymer processing industry is known to use VOCs extensively for polymerization, fractionation, plasticization, degradation, extraction and purification. More environmentally-friendly methods to circumvent the use of these toxic and hazardous
compounds are being explored. The use of dense gases in polymer processing can respond to the need for more environmentally-friendly industrial processes. Products with
high-purity, sterility, and porosity can be achieved using dense gas technology (DGT). Currently, DGT has been used for different aspects of polymer processing including polymerization, micronization, and impregnation. Due to its high solubility in polymers and diffusivity, dense CO2 can penetrate and plasticize polymers, whilst impregnating them with low-molecular weight CO2-soluble compounds. The dense CO2 properties of inertness, non-toxicity, and affinity for various therapeutic compounds are specifically advantageous to the medical and biomedical industries. Biodegradable polymers and
other medical-grade polymers have benefited from the pplication of DGT. The aim of this review was to show the versatility of dense CO2 for polymer processing applications, specifically polymerization, polymer blend preparation, drug loading and sterilization.
Areas covered: This review provides an overview of recent advances in DDS strategies for the treatment ovarian cancers. Nano-sized systems, including nanoparticles, micelles, liposomes and drug conjugates; microspheres; implants and injectable depots are discussed. The advantages, limitations and clinical potential of these strategies are also outlined.
Expert opinion: Nano-sized DDS enable passive targeting to tumors due to their size, and further improvements in tumor localization can be made using targeting moieties. Microspheres, implants and injectable depots have been investigated for peritoneal localized and sustained therapy. Overall, the benefits of using DDS for ovarian cancer therapy include higher drug levels at the diseased site, circumvention of drug resistance mechanisms, minimization of non-specific toxicities, improvements in solubility of poorly soluble drugs and elimination of toxicities associated with conventionally used pharmaceutical excipients.
product that may be used as a contrasting agent for MRI. There are several methods that can be employed to coat SPIONs.
However, many of the current methods employ toxic organic solvents which can be difficult to remove from the product
solution. The encapsulation and characterization of SPIONs in Eudragit was done using a supercritical antisolvent system
(SAS) with ethanol as the solvent and supercritical carbon dioxide (SC-CO2) as the antisolvent. Particles of diameters less
than 200 nm were produced which had preserved superparamagnetic properties. An encapsulation efficiency of 70% was
achieved.
There are distinct turning points when biomaterial research is thought to have evolved. I believe we are currently in the third generation and slowly shifting to the fourth (more on this later).
compounds (VOCs) is a practice that is being limited and minimized world-wide. These VOCs are not only damaging to the environment, but are also an occupational hazard. The polymer processing industry is known to use VOCs extensively for polymerization, fractionation, plasticization, degradation, extraction and purification. More environmentally-friendly methods to circumvent the use of these toxic and hazardous
compounds are being explored. The use of dense gases in polymer processing can respond to the need for more environmentally-friendly industrial processes. Products with
high-purity, sterility, and porosity can be achieved using dense gas technology (DGT). Currently, DGT has been used for different aspects of polymer processing including polymerization, micronization, and impregnation. Due to its high solubility in polymers and diffusivity, dense CO2 can penetrate and plasticize polymers, whilst impregnating them with low-molecular weight CO2-soluble compounds. The dense CO2 properties of inertness, non-toxicity, and affinity for various therapeutic compounds are specifically advantageous to the medical and biomedical industries. Biodegradable polymers and
other medical-grade polymers have benefited from the pplication of DGT. The aim of this review was to show the versatility of dense CO2 for polymer processing applications, specifically polymerization, polymer blend preparation, drug loading and sterilization.